EZZ Life Science soars after inking $21m Southeast Asian distribution deal

EZZ Life Science inks three-year $21m distribution deal with ROFA Enterprises across three key Southeast Asian markets.

EZZ will sell its healthcare products in key Southeast Asian markets under a new distribution deal. Pic via Getty Images.

• EZZ enters three-year distribution deal for sale of EZZ-branded healthcare products in Thailand, Vietnam and Singapore

• Agreement with ROFA Enterprises secures minimum purchase value of $21 million over contract term

• EZZ shares have surged nearly 30% on their highest trading volume in over three months, following the news.

  

Special Report: EZZ Life Science has inked a three-year $21 million distribution deal with ROFA Enterprises Pty Ltd for the sale of EZZ-branded healthcare products across three key Southeast Asian markets.

EZZ Life Science (ASX:EZZ) said the three-year agreement deal started in June 2025 and granted ROFA distribution rights for EZZ-branded products across Thailand, Vietnam and Singapore.

EZZ said the deal secures a minimum purchase value of A$21 million over the contract term and aligns with the company’s strategy to accelerate growth in key markets in Southeast Asia, one of the fastest-growing regions for consumer health and wellness.

With rising health consciousness, expanding middle-class populations and increasing demand for high-quality genomic wellness and functional health products, EZZ said Southeast Asian markets offered significant commercial upside and long-term growth potential.

Export specialist to Southeast Asia

ROFA is an Australian-owned company specialising in the export of premium Australian and New Zealand dairy, health and beauty products to Southeast Asia.

With more than a decade of experience, ROFA has built a robust omnichannel distribution network across Vietnam, Thailand and Cambodia, reaching more than 10,000 pharmacies, mother and baby stores, supermarkets and online platforms.

The company is recognised for its partnerships with trusted global brands and commitment to delivering tailored marketing support and deep retail expertise to drive brand growth across Asia.

Under the deal ROFA will be responsible for all marketing, distribution and logistics costs in the region.

EZZ said the deal included clear terms for market exclusivity, branding integrity, and compliance with its high standards of product storage, marketing and distribution.

The news comes as EZZ plans to also enter the US – the world’s largest healthcare market – in H2 CY25.

EZZ has entered a manufacturing deal with GLSP Inc to serve as its US-based manufacturer for its products in the North American market.

‘Ideal partner to help scale’ in Southeast Asia

EZZ chairman Glenn Cross said the deal was a major milestone in its regional expansion strategy.

“ROFA’s established presence and deep experience in Southeast Asia make them an ideal partner to help scale EZZ’s brand footprint across these important markets,” he said.

“We look forward to building a strong and successful partnership.”

This article was developed in collaboration with EZZ Life Science, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Originally published as EZZ Life Science soars after inking $21m Southeast Asian distribution deal